Testosterone in Castration-Resistant Prostate Cancer
Status:
Withdrawn
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
1. To assess the prostate-specific antigen (PSA)-response (50% decline) to Testosterone
Replacement Therapy (TRT) in men with "intermediate and good-risk" Castration-Resistant
Prostate Cancer (CRPC).
Secondary Objectives:
1. To assess the objective response and time-to-progression with TRT in CRPC.
2. To assess serial changes in quality of life with TRT in these CRPC subsets.
3. Translational: To study kinetics of circulating tumor cells with TRT and molecular
correlates of response to TRT in CRPC.